Greater striatal responses to medication in Parkinson׳s disease are associated with better task-switching but worse reward performance

Neuropsychologia

Volumn 62, Issue , 2014, Pages 390-397

  Aarts, Esther ^a   Nusselein, Abraham A M ^a   Smittenaar, Peter ^a   Helmich, Rick C ^a,b   Bloem, Bastiaan R ^b   Cools, Roshan ^a,b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cognition; Dopamine; fMRI; Parkinson s disease; Reward; Striatum

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ANTIPARKINSON AGENT; OXYGEN;

ADULT; ARTICLE; BOLD SIGNAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DISEASE SEVERITY; DORSOMEDIAL STRIATUM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; MORNING DOSAGE; MUSCLE TWITCH; PARKINSON DISEASE; RESPONSE TIME; REWARD; TASK PERFORMANCE; TREATMENT RESPONSE; VENTROMEDIAL STRIATUM; ATTENTION; BLOOD; DRUG EFFECTS; ELECTROMYOGRAPHY; HEMISPHERIC DOMINANCE; LEARNING; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; REACTION TIME; VASCULARIZATION;

ANTIPARKINSON AGENTS; ASSOCIATION LEARNING; ATTENTION; CORPUS STRIATUM; DOPAMINE AGENTS; ELECTROMYOGRAPHY; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PARKINSON DISEASE; REACTION TIME; REWARD;

EID: 84929504336     PISSN: 00283932     EISSN: 18733514     Source Type: Journal    
DOI: 10.1016/j.neuropsychologia.2014.05.023     Document Type: Article

References (58)

1. Aarts, E., Helmich, R.C., Janssen, M., Oyen, W.J., Bloem, B.R., Cools, R., Aberrant reward processing in Parkinson׳s disease is associated with dopamine cell loss. Neuroimage 59 (2012), 3339–3346.
2. Aarts, E., Roelofs, A., Franke, B., Rijpkema, M., Fernandez, G., Helmich, R.C., et al. Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging. Neuropsychopharmacology 35 (2010), 1943–1951.
3. Argyelan, M., Carbon, M., Ghilardi, M.F., Feigin, A., Mattis, P., Tang, C., et al. Dopaminergic suppression of brain deactivation responses during sequence learning. Journal of Neuroscience 28 (2008), 10687–10695.
4. Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., An inventory for measuring depression. Archives of General Psychiatry 4 (1961), 561–571.
5. Bond, A., Lader, M., The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology 47 (1974), 211–218.
6. Brett, M., Anton, J. L., Valabregue, R., & Poline, J. B. (2002. Region of interest analysis using an SPM toolbox. In Proceedings of 8th international conference on functional mapping of the human brain (Vol. 16(2)). Sendai, Japan: NeuroImage.
7. Buckholtz, J.W., Treadway, M.T., Cowan, R.L., Woodward, N.D., Benning, S.D., Li, R., et al. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nature Neuroscience 13 (2010), 419–421.
8. Cilia, R., Ko, J.H., Cho, S.S., van Eimeren, T., Marotta, G., Pellecchia, G., et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson׳s disease and pathological gambling. Neurobiology of Disease 39 (2010), 98–104.
9. Cools, R., Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson׳s disease. Neuroscience & Biobehavioral Reviews 30 (2006), 1–23.
10. Cools, R., Dopaminergic control of the striatum for high-level cognition. Current Opinion in Neurobiology 21 (2011), 402–407.
11. Cools, R., Barker, R.A., Sahakian, B.J., Robbins, T.W., Enhanced or impaired cognitive function in Parkinson׳s disease as a function of dopaminergic medication and task demands. Cerebral Cortex 11 (2001), 1136–1143.
12. Cools, R., Barker, R.A., Sahakian, B.J., Robbins, T.W., L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson׳s disease. Neuropsychologia 41 (2003), 1431–1441.
13. Cools, R., D'Esposito, M., Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biological Psychiatry 69 (2011), e113–125.
14. Cools, R., Lewis, S.J., Clark, L., Barker, R.A., Robbins, T.W., L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson׳s disease. Neuropsychopharmacology 32 (2007), 180–189.
15. Cools, R., Stefanova, E., Barker, R.A., Robbins, T.W., Owen, A.M., Dopaminergic modulation of high-level cognition in Parkinson׳s disease: the role of the prefrontal cortex revealed by PET. Brain 125 (2002), 584–594.
16. Dagher, A., Owen, A.M., Boecker, H., Brooks, D.J., The role of the striatum and hippocampus in planning: a PET activation study in Parkinson׳s disease. Brain 124 (2001), 1020–1032.
17. Dagher, A., Robbins, T.W., Personality, addiction, dopamine: insights from Parkinson׳s disease. Neuron 61 (2009), 502–510.
18. Dubois, B., Slachevsky, A., Litvan, I., Pillon, B., The FAB: a frontal assessment battery at bedside. Neurology 55 (2000), 1621–1626.
19. Duzel, E., Bunzeck, N., Guitart-Masip, M., Wittmann, B., Schott, B.H., Tobler, P.N., Functional imaging of the human dopaminergic midbrain. Trends in Neurosciences 32 (2009), 321–328.
20. Evans, A.H., Strafella, A.P., Weintraub, D., Stacy, M., Impulsive and compulsive behaviors in Parkinson׳s disease. Movement Disorder 24 (2009), 1561–1570.
21. Fahn, S., Elton, R.L., MotUD, C., Unified Parkinson׳s disease rating scale. Fahn, S., Marsden, C.D., Caine, D., Goldstein, M., (eds.) Recent developments in Parkinson׳s disease, 1987, McMillan Health Care Information, Florham Park, NJ.
22. Fearnley, J.M., Lees, A.J., Ageing and Parkinson׳s disease: substantia nigra regional selectivity. Brain 114:Pt 5 (1991), 2283–2301.
23. Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12 (1975), 189–198.
24. Friston, K.J., Ashburner, J., Frith, C.D., Poline, J.B., Heather, J.D., Frackowiak, R.S., Spatial registration and normalization of images. Human Brain Mapping 3 (1995), 165–189.
25. Gotham, A.M., Brown, R.G., Marsden, C.D., ‘Frontal’ cognitive function in patients with Parkinson׳s disease ‘on’ and ‘off’ levodopa. Brain 111:Pt 2 (1988), 299–321.
26. Haaxma, C.A., Bloem, B.R., Borm, G.F., Horstink, M.W., Comparison of a timed motor test battery to the unified Parkinson׳s disease rating scale-III in Parkinson׳s disease. Movement Disorder 23 (2008), 1707–1717.
27. Haber, S.N., Fudge, J.L., McFarland, N.R., Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. Journal of Neuroscience 20 (2000), 2369–2382.
28. Hayes, A.E., Davidson, M.C., Keele, S.W., Rafal, R.D., Toward a functional analysis of the basal ganglia. Journal of Cognitive Neuroscience 10 (1998), 178–198.
29. Helmich, R.C., Derikx, L.C., Bakker, M., Scheeringa, R., Bloem, B.R., Toni, I., Spatial remapping of cortico-striatal connectivity in Parkinson׳s disease. Cerebral Cortex 20 (2010), 1175–1186.
30. Helmich, R.C., Janssen, M.J., Oyen, W.J., Bloem, B.R., Toni, I., Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Annals of Neurology 69 (2011), 269–281.
31. Holden, A., Wilman, A., Wieler, M., Martin, W.R., Basal ganglia activation in Parkinson׳s disease. Parkinsonism & Related Disorders 12 (2006), 73–77.
32. Kish, S.J., Shannak, K., Hornykiewicz, O., Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson׳s disease. Pathophysiologic and clinical implications. New England Journal of Medicine 318 (1988), 876–880.
33. Knutson, B., Gibbs, S.E., Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology 191 (2007), 813–822.
34. Kwak, Y., Muller, M.L., Bohnen, N.I., Dayalu, P., Seidler, R.D., l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson׳s disease. Behavioural Brain Research 230 (2012), 116–124.
35. Lewis, R., & Kupke, T. (1977. The Lafayette clinic repeatable neuropsychological test battery: its development and research applications. In Proceedings of annual meeting of the southeastern psychological association. Hollywood, FL.
36. MacDonald, P.A., MacDonald, A.A., Seergobin, K.N., Tamjeedi, R., Ganjavi, H., Provost, J.S., et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson׳s disease: support from functional MRI. Brain 134 (2011), 1447–1463.
37. Marklund, P., Larsson, A., Elgh, E., Linder, J., Riklund, K.A., Forsgren, L., et al. Temporal dynamics of basal ganglia under-recruitment in Parkinson׳s disease: transient caudate abnormalities during updating of working memory. Brain 132 (2009), 336–346.
38. Mattay, V.S., Tessitore, A., Callicott, J.H., Bertolino, A., Goldberg, T.E., Chase, T.N., et al. Dopaminergic modulation of cortical function in patients with Parkinson׳s disease. Annals of Neurology 51 (2002), 156–164.
39. Millan, M.J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.A., Newman-Tancredi, A., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 303 (2002), 791–804.
40. Nelson, H.E., O'Connell, A., Dementia: the estimation of premorbid intelligence levels using the new adult reading test. Cortex 14 (1978), 234–244.
41. Niv, Y., Daw, N.D., Joel, D., Dayan, P., Tonic dopamine: opportunity costs and the control of response vigor. Psychopharmacology 191 (2007), 507–520.
42. Patton, J.H., Stanford, M.S., Barratt, E.S., Factor structure of the Barratt impulsiveness scale. Journal of Clinical Psychology 51 (1995), 768–774.
43. Poser, B.A., Versluis, M.J., Hoogduin, J.M., Norris, D.G., BOLD contrast sensitivity enhancement and artifact reduction with multiecho EPI: parallel-acquired inhomogeneity-desensitized fMRI. Magnetic Resonance in Medicine 55 (2006), 1227–1235.
44. Salthouse, T.A., Hedden, T., Interpreting reaction time measures in between-group comparisons. Journal of Clinical and Experimental Neuropsychology 24 (2002), 858–872.
45. Schmand, B., Bakker, D., Saan, R., Louman, J., The Dutch reading test for adults: a measure of premorbid intelligence level. Tijdschrift voor gerontologie en geriatrie 22 (1991), 15–19.
46. Schott, B.H., Minuzzi, L., Krebs, R.M., Elmenhorst, D., Lang, M., Winz, O.H., et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. Journal of Neuroscience 28 (2008), 14311–14319.
47. Schultz, W., Getting formal with dopamine and reward. Neuron 36 (2002), 241–263.
48. Shook, S.K., Franz, E.A., Higginson, C.I., Wheelock, V.L., Sigvardt, K.A., Dopamine dependency of cognitive switching and response repetition effects in Parkinson׳s patients. Neuropsychologia 43 (2005), 1990–1999.
49. Smittenaar, P., Chase, H.W., Aarts, E., Nusselein, B., Bloem, B.R., Cools, R., Decomposing effects of dopaminergic medication in Parkinson׳s disease on probabilistic action selection—learning or performance?. European Journal of Neuroscience 35 (2012), 1144–1151.
50. Spraker, M.B., Prodoehl, J., Corcos, D.M., Comella, C.L., Vaillancourt, D.E., Basal ganglia hypoactivity during grip force in drug naive Parkinson׳s disease. Human Brain Mapping 31 (2010), 1928–1941.
51. Swainson, R., Rogers, R.D., Sahakian, B.J., Summers, B.A., Polkey, C.E., Robbins, T.W., Probabilistic learning and reversal deficits in patients with Parkinson׳s disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 38 (2000), 596–612.
52. Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15 (2002), 273–289.
53. van Eimeren, T., Ballanger, B., Pellecchia, G., Miyasaki, J.M., Lang, A.E., Strafella, A.P., Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson׳s disease?. Neuropsychopharmacology 34 (2009), 2758–2766.
54. Voon, V., Pessiglione, M., Brezing, C., Gallea, C., Fernandez, H.H., Dolan, R.J., et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65 (2010), 135–142.
55. Voon, V., Sohr, M., Lang, A.E., Potenza, M.N., Siderowf, A.D., Whetteckey, J., et al. Impulse control disorders in parkinson disease: A multicenter case-control study. Annals of Neurology 69 (2011), 986–996.
56. Vriend, C., Pattij, T., van der Werf, Y.D., Voorn, P., Booij, J., Rutten, S., et al. Depression and impulse control disorders in Parkinson׳s disease: two sides of the same coin?. Neuroscience & Biobehavioral Reviews 38 (2014), 60–71.
57. Weintraub, D., Koester, J., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology 67 (2010), 589–595.
58. Wenzelburger, R., Zhang, B.R., Pohle, S., Klebe, S., Lorenz, D., Herzog, J., et al. Force overflow and levodopa-induced dyskinesias in Parkinson׳s disease. Brain 125 (2002), 871–879.